Figure 2
From: Extraskeletal myxoid chondrosarcoma: tumor response to sunitinib
[18F]fluorodeoxyglucose–positron emission tomography scan (PET) tumor assessment. In panels A and B (white arrows) PET shows a marked decrease in maximum SUV comparing the tumor before and after 4 weeks of treatment. Panel C shows an interval tumor progression at 6 months from baseline, i.e. after 2 months from sunitinib interruption and treatment with antibiotics.